Rise in Cannabinoid Hyperemesis Syndrome Cases Noted Amid Increased Cannabis Legalization
A recent study by the University of Illinois Chicago indicates a significant increase in diagnosed cases of Cannabinoid Hyperemesis Syndrome (CHS) between 2016 and 2022. This condition, characterized by recurrent bouts of severe vomiting, has seen a sevenfold jump in diagnoses at hospital emergency departments nationwide, coinciding with increased cannabis legalization and product potency.
Understanding Cannabinoid Hyperemesis Syndrome (CHS)
Jared Panks, a former paramedic and medical cannabis farm co-founder, reported experiencing severe, cyclic vomiting episodes since 2013, which lasted for days and resulted in significant weight loss and physical strain. His symptoms, including morning vomiting, continuous nausea, and relief from hot showers, led to a diagnosis of CHS. This condition, sometimes referred to as 'scromiting' due to associated screaming and vomiting, can be debilitating.
While cannabis is known for its anti-nausea properties, particularly with synthetic THC approved for chemotherapy-induced nausea, high or prolonged consumption can lead to adverse effects. CHS is understood to involve the endocannabinoid system, which regulates digestion. Research indicates that most individuals diagnosed with CHS are long-term, daily users, often consuming high-potency cannabis or concentrates.
Statistical Trends and Demographics
The UIC study found that CHS cases peaked at 33 per 100,000 ER visits during the COVID-19 pandemic, a period when substance abuse generally increased. The rise in cases was predominantly observed among young adults aged 18 to 35, with a majority being men.
Professor James Swartz, the lead author of the UIC study, suggests that increased state-level cannabis legalization and higher product potency are primary factors contributing to the observed increase. Swartz emphasizes the reality and growing concern of CHS, urging clinicians to consider it in patient diagnoses and advising consumers to evaluate product potency and usage levels.
User Experiences and Advocacy for Research
Tim Blake, founder of The Emerald Cup, reported experiencing cyclic vomiting related to cannabis use years ago. He found relief after several months of abstinence, allowing THC, which accumulates in fatty tissues, to clear his system. Blake now practices annual abstinence periods and advocates for more moderate cannabis consumption, particularly discouraging very high-potency products.
Jared Panks and his wife, who established Deafining Cannabis, advocate for a focus on cannabis terpenes rather than solely THC percentages to better understand individual body reactions. Panks hopes to contribute to further research into CHS mechanisms and potential cures. Alice Moon, another cannabis advocate affected by CHS, works to spread awareness about the condition despite being unable to consume cannabis herself.
CHS research is in its early stages. The World Health Organization recently recognized it as a medical condition. Currently, complete abstinence from cannabis is identified as the only known cure. Further research is sought to understand the causes, potential treatments, and varying effects on individuals.